2031 related articles for article (PubMed ID: 34145792)
1. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
[TBL] [Abstract][Full Text] [Related]
2. The update of chimeric antigen receptor-T cells therapy in glioblastoma.
Chou CJ; Lin CF; Chen YW; Huang PI; Yang YP; Wang ML; Hung KF; Lee YY
J Chin Med Assoc; 2020 May; 83(5):442-445. PubMed ID: 32217989
[TBL] [Abstract][Full Text] [Related]
3. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
Sengupta S; Mao G; Gokaslan ZS; Sampath P
Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
Feldman L; Brown C; Badie B
Neurosurgery; 2021 May; 88(6):1056-1064. PubMed ID: 33575786
[TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.
Li L; Zhu X; Qian Y; Yuan X; Ding Y; Hu D; He X; Wu Y
Front Immunol; 2020; 11():594271. PubMed ID: 33224149
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Yoo HJ; Harapan BN
Immunol Res; 2021 Dec; 69(6):471-486. PubMed ID: 34554405
[TBL] [Abstract][Full Text] [Related]
8. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma.
Agliardi G; Liuzzi AR; Hotblack A; De Feo D; Núñez N; Stowe CL; Friebel E; Nannini F; Rindlisbacher L; Roberts TA; Ramasawmy R; Williams IP; Siow BM; Lythgoe MF; Kalber TL; Quezada SA; Pule MA; Tugues S; Straathof K; Becher B
Nat Commun; 2021 Jan; 12(1):444. PubMed ID: 33469002
[TBL] [Abstract][Full Text] [Related]
10. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment.
Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS
Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081
[TBL] [Abstract][Full Text] [Related]
11. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma.
Zhou S; Sun H; Choi SI; Yin J
Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?
Prinzing BL; Gottschalk SM; Krenciute G
Expert Rev Anticancer Ther; 2018 May; 18(5):451-461. PubMed ID: 29533108
[TBL] [Abstract][Full Text] [Related]
13. A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives.
Montoya M; Gallus M; Phyu S; Haegelin J; de Groot J; Okada H
Cells; 2024 Apr; 13(9):. PubMed ID: 38727262
[TBL] [Abstract][Full Text] [Related]
14. Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P; Downey KM; Hegde B; Almeida ND; Okada H
Front Immunol; 2018; 9():3062. PubMed ID: 30740109
[TBL] [Abstract][Full Text] [Related]
15. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages.
Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C
ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338
[TBL] [Abstract][Full Text] [Related]
16. Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Salinas RD; Durgin JS; O'Rourke DM
CNS Drugs; 2020 Feb; 34(2):127-145. PubMed ID: 31916100
[TBL] [Abstract][Full Text] [Related]
17. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: past, present and future developments.
Soler DC; Kerstetter-Fogle A; McCormick TS; Sloan AE
J Neurooncol; 2022 Jan; 156(1):81-96. PubMed ID: 34825292
[TBL] [Abstract][Full Text] [Related]
18. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
19. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
20. CAR T cells and checkpoint inhibition for the treatment of glioblastoma.
Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH
Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536
[No Abstract] [Full Text] [Related]
[Next] [New Search]
